CIK 0001175680 · Non-accelerated filer<br>Smaller reporting company
CytoDyn Inc.
Sign in to watch- Ticker
- CYDY
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- May 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753056237
- Phone
- 360-980-8524
- Business address
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Former names
- CYTODYN INC, REXRAY CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Option exercise | +233,100 | $0.49 | $114K | 672,681 |
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Option exercise | +98,402 | $0.57 | $56K | 771,083 |
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Sale | −487,002 | $4.95 | $2.4M | 284,081 |
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +155,500 | 0 | ||
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +233,100 | 116,900 | ||
| 2020-12-18 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +98,402 | 201,598 | ||
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Option exercise | +32,000 | $0.39 | $12K | 316,081 |
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Sale | −32,000 | $4.55 | $146K | 284,081 |
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +32,000 | 155,500 | ||
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Option exercise | +32,000 | $0.39 | $12K | 316,081 |
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Sale | −32,000 | $4.55 | $146K | 284,081 |
| 2020-12-17 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +32,000 | 155,500 | ||
| 2020-11-02 | Naydenov Jordan G Director | Purchase | +193,500 | $2.57 | $497K | 6,451,323 |
| 2020-10-23 | Colachis Arian GC and Corporate Secretary | Purchase | +10,000 | $2.50 | $25K | 80,000 |
| 2020-10-23 | Naydenov Jordan G Director | Purchase | +120,000 | $2.49 | $298K | 6,257,823 |
| 2020-10-16 | Rahman Mahboob U Chief Scientific Officer | Grant or award | +200,000 | 200,000 | ||
| 2020-09-30 | Colachis Arian GC and Corporate Secretary | Grant or award | +70,000 | 70,000 | ||
| 2020-09-30 | Colachis Arian GC and Corporate Secretary | Grant or award · Non-qualified Stock Option | +150,000 | 150,000 | ||
| 2020-09-30 | Ray Nitya G. Chief Technology Officer | Grant or award | +200,000 | 200,000 | ||
| 2020-09-30 | Ray Nitya G. Chief Technology Officer | Grant or award · Non-qualified Stock Option | +500,000 | 500,000 |
Page 11 of 33 · 652 trades